Pain Research and Management

Pain Research and Management / 2004 / Article

Editorial | Open Access

Volume 9 |Article ID 979013 | https://doi.org/10.1155/2004/979013

Dwight E Moulin, "Managing Cancer Pain - Simple Rules, Major Benefits", Pain Research and Management, vol. 9, Article ID 979013, 1 page, 2004. https://doi.org/10.1155/2004/979013

Managing Cancer Pain - Simple Rules, Major Benefits

Abstract

In the developed world, approximately one in three individuals will be diagnosed with cancer and one-half of those will die of progressive disease (1). At least 75% of patients with cancer develop pain before death. It is therefore not surprising that pain is one of the most feared consequences of cancer for both patients and families (2). The good news is that cancer pain can be controlled with relatively simple means in more than 80% of cases based on guidelines from the World Health Organization (3). Mild pain can be treated with acetaminophen or nonsteroidal anti-inflammatory drugs (Step 1 of the analgesic ladder). Moderate pain requires the addition of a 'minor' opioid such as codeine (Step 2), and severe pain mandates the use of a major opioid analgesic such as morphine (Step 3). In this issue of Pain Research & Management, Gallagher et al (pages 188-194) highlight some of the barriers to adequate cancer pain management based on a cross-sectional survey of British Columbian physicians. The survey response rate of 69% attests to the validity of their findings.

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views60
Downloads188
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.